文献速递新发突发、热带与寄生虫病

美国静脉青蒿琥酯治疗重症疟疾的安全性与有效性(2019年4月至2020年12月)

Safety and Effectiveness of Intravenous Artesunate for Treatment of Severe Malaria in the United States-April 2019 Through December 2020.
PubMed 文献 · Clin Infect Dis · 2021-01-01

结果显示IVAS相关不良事件报告率为4.8%,5例(1.8%)死亡均归因于重症疟疾,IVAS是美国治疗重症疟疾安全有效的药物,及时给药可挽救生命。

要点

  • 170例有信息者中159例(93.5%)在第三剂IVAS时寄生虫血症≤1%。
  • IVAS相关不良事件报告率为4.8%(271例中13例),8例出现可缓解的延迟性溶血。
  • 5例(1.8%)死亡,均归因于重症疟疾本身。

核心结论

  • IVAS是美国治疗重症疟疾安全有效的药物,及时给药可挽救生命。

研究设计与样本

  • 共纳入280例患者,采用比例、中位数、四分位距(IQR)及比例差异显著性检验进行描述。

主要发现

  • 280例中男性61.4%、黑人75.0%,中位年龄35岁(IQR 15.8-53.9),83.6%为恶性疟原虫,中位寄生虫血症8.0%(IQR 4.6-13.2)。
  • 170例有信息者中159例(93.5%)在第三剂IVAS时达到≤1%寄生虫血症,中位时间17.6小时(IQR 10.8-28.8),0%寄生虫血症中位时间37.2小时(IQR 27.2-55.2)。
  • 寄生虫密度>10%及需辅助治疗者寄生虫清除时间显著更长。
  • IVAS相关不良事件报告率4.8%(271例中13例),8例出现可缓解的延迟性溶血。
  • 死亡5例(1.8%),均归因于重症疟疾。

临床怎么用

  • 对符合重症疟疾标准的患者应及时给予IVAS,以降低死亡风险。
  • 寄生虫密度>10%或需辅助治疗者应预期更长的寄生虫清除时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Severe malaria can be deadly and requires treatment with intravenous artesunate (IVAS). The Centers for Disease Control and Prevention provided IVAS starting 1 April 2019 for all patients with severe malaria in the United States. This study describes the safety and effectiveness of IVAS in these patients. METHODS: Patients meeting criteria for severe malaria April 2019-December 2020 who received IVAS were included. Demographic, clinical, laboratory, adverse event, and outcome information were collected. Clinical presentation, time to reach 1% and 0% parasitemia, adverse events, and death were described using proportions, medians, interquartile range (IQR), and tests of significance for differences in proportions. RESULTS: Of 280 patients included, the majority were male (61.4%), Black (75.0%), with a median age of 35 years (IQR: 15.8-53.9). Most had Plasmodium falciparum (83.6%) with median parasitemia of 8.0% (IQR: 4.6-13.2). Of 170 patients with information, 159 (93.5%) reached ≤1% parasitemia by the third IVAS dose with a median time of 17.6 hours (IQR: 10.8-28.8), and 0% parasitemia in a median of 37.2 hours (IQR 27.2-55.2). Patients with parasite densities >10% and those requiring adjunct therapy had significantly higher parasite clearance times. Adverse events associated with IVAS were reported in 4.8% (n = 13 of 271). Eight patients had post-artesunate delayed hemolysis that resolved. There were 5 (1.8%) deaths, all attributable to severe malaria. CONCLUSIONS: IVAS is a safe and effective drug for the treatment of severe malaria in the United States; timely administration can be lifesaving.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Abanyie F, Acharya SD, Leavy I, et al. Safety and Effectiveness of Intravenous Artesunate for Treatment of Severe Malaria in the United States-April 2019 Through December 2020. Clin Infect Dis. 2021. PMID: 34314501. doi:10.1093/cid/ciab570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。